# Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis

> **NCT06039189** · PHASE3 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 338 (actual)

## Conditions studied

- Moderate Plaque Psoriasis

## Interventions

- **DRUG:** Guselkumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06039189
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-24
- **Primary completion:** 2025-04-14
- **Final completion:** 2025-04-14
- **Target enrollment:** 338 (ACTUAL)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06039189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06039189, "Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT06039189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*